Virginia Foxx bought AbbVie Inc (NYSE: ABBV)
Virginia Foxx (R-NC), a U.S. Representative, has disclosed 1 trade in AbbVie Inc (ABBV) since 2024, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Virginia Foxx bought $1,001 - $15,000 of AbbVie Inc (NYSE: ABBV) on December 6, 2024. Since that trade, ABBV is up +53.69% against the S&P 500 up +24.22%, an outperformance of +29.47%.
Data updated
Virginia Foxx's ABBV trades vs the price
ABBV is up +53.69% since Virginia Foxx bought on December 6, 2024, versus +24.22% for the S&P 500.
Performance since this trade
All Virginia Foxx ABBV trades
Virginia Foxx & ABBV trading FAQ
Is it legal for Virginia Foxx to trade AbbVie Inc (ABBV) stock?
Yes. Members of Congress are allowed to trade individual stocks, including AbbVie Inc (ABBV), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Virginia Foxx buy ABBV?
Virginia Foxx disclosed a purchase of $1,001 - $15,000 of AbbVie Inc (ABBV) on December 6, 2024, according to public STOCK Act filings.
How has ABBV performed since Virginia Foxx's trade?
Since Virginia Foxx bought ABBV on December 6, 2024, the stock is up +53.69%, versus +24.22% for the S&P 500 over the same period, an outperformance of +29.47%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional ABBV trades?
Quantellect tracks every disclosed congressional trade in AbbVie Inc (ABBV) on the AbbVie Inc congressional trading page, which aggregates filings across all members of Congress.
Virginia Foxx's ABBV tradesAll congressional filings for AbbVie IncVirginia Foxx's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.